These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 33860210)

  • 1. Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions.
    Thévenin M; Chen G; Kantham S; Sun C; Glogauer M; Young RN
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):908-925. PubMed ID: 33860210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and synthesis of novel bone-targeting dual-action pro-drugs for the treatment and reversal of osteoporosis.
    Arns S; Gibe R; Moreau A; Monzur Morshed M; Young RN
    Bioorg Med Chem; 2012 Mar; 20(6):2131-40. PubMed ID: 22341574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and Pharmacokinetics of a Bone-Targeting Dual-Action Prodrug for the Treatment of Osteoporosis.
    Xie H; Chen G; Young RN
    J Med Chem; 2017 Aug; 60(16):7012-7028. PubMed ID: 28699744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting therapeutics to bone by conjugation with bisphosphonates.
    Young RN; Grynpas MD
    Curr Opin Pharmacol; 2018 Jun; 40():87-94. PubMed ID: 29626715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel EP4 receptor agonist-bisphosphonate conjugate drug (C1) promotes bone formation and improves vertebral mechanical properties in the ovariectomized rat model of postmenopausal bone loss.
    Liu CC; Hu S; Chen G; Georgiou J; Arns S; Kumar NS; Young RN; Grynpas MD
    J Bone Miner Res; 2015 Apr; 30(4):670-80. PubMed ID: 25284325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination of the rat in vivo pharmacokinetic profile of a bone-targeting dual-action pro-drug for treatment of osteoporosis.
    Chen G; Arns S; Young RN
    Bioconjug Chem; 2015 Jun; 26(6):1095-103. PubMed ID: 25945831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Bone Effects of a Novel Bisphosphonate-EP4a Conjugate Drug (C3) for Reversing Osteoporotic Bone Loss in an Ovariectomized Rat Model.
    Sheikh Z; Chen G; Al-Jaf F; Thévenin M; Banks K; Glogauer M; Young RN; Grynpas MD
    JBMR Plus; 2019 Dec; 3(12):e10237. PubMed ID: 31844825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.
    Hu S; Liu CC; Chen G; Willett T; Young RN; Grynpas MD
    Osteoporos Int; 2016 Feb; 27(2):797-808. PubMed ID: 26272313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of bone morphogenetic protein-induced bone mass by local delivery of a prostaglandin E EP4 receptor agonist.
    Toyoda H; Terai H; Sasaoka R; Oda K; Takaoka K
    Bone; 2005 Oct; 37(4):555-62. PubMed ID: 16027058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone.
    Kato N; Kitahara K; Rittling SR; Nakashima K; Denhardt DT; Kurosawa H; Ezura Y; Noda M
    J Endocrinol; 2007 Apr; 193(1):171-82. PubMed ID: 17400814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The selective prostaglandin EP4 agonist, APS-999 Na, induces follicular growth and maturation in the rat ovary.
    El-Nefiawy N; Abdel-Hakim K; Kanayama N
    Eur J Endocrinol; 2005 Feb; 152(2):315-23. PubMed ID: 15745941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model.
    Namikawa T; Terai H; Hoshino M; Kato M; Toyoda H; Yano K; Nakamura H; Takaoka K
    Spine (Phila Pa 1976); 2007 Oct; 32(21):2294-9. PubMed ID: 17906568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of bone-bonding ability of bioactive titanium by prostaglandin E2 receptor selective agonist.
    Onishi E; Fujibayashi S; Takemoto M; Neo M; Maruyama T; Kokubo T; Nakamura T
    Biomaterials; 2008 Mar; 29(7):877-83. PubMed ID: 18045684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta.
    Boraschi-Diaz I; Chen G; Polak-Nachumow J; Young RN; Rauch F
    Bone; 2021 Apr; 145():115867. PubMed ID: 33524637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EP4 agonist accelerates osteoinduction and degradation of beta-tricalcium phosphate by stimulating osteoclastogenesis.
    Nasu T; Takemoto M; Akiyama N; Fujibayashi S; Neo M; Nakamura T
    J Biomed Mater Res A; 2009 Jun; 89(3):601-8. PubMed ID: 18437696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of prostaglandin E(2)-specific receptor 4 antagonist inhibits lipopolysaccharide-induced osteoclastogenesis in rat periodontal tissue.
    Oka H; Miyauchi M; Furusho H; Nishihara T; Takata T
    J Periodontol; 2012 Apr; 83(4):506-13. PubMed ID: 21910594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of basic fibroblast growth factor and a prostaglandin E2 receptor subtype 4 agonist on osteoblastogenesis and adipogenesis in aged ovariectomized rats.
    Aguirre JI; Leal ME; Rivera MF; Vanegas SM; Jorgensen M; Wronski TJ
    J Bone Miner Res; 2007 Jun; 22(6):877-88. PubMed ID: 17352655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone formation and tooth movement are synergistically enhanced by administration of EP4 agonist.
    Chung CJ; Baik HS; Soma K
    Am J Orthod Dentofacial Orthop; 2007 Oct; 132(4):427.e13-20. PubMed ID: 17920491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis.
    Hayashi K; Fotovati A; Ali SA; Oda K; Oida H; Naito M
    J Bone Joint Surg Br; 2005 Aug; 87(8):1150-6. PubMed ID: 16049256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E2 receptor (EP4) selective agonist (ONO-4819.CD) accelerates bone repair of femoral cortex after drill-hole injury associated with local upregulation of bone turnover in mature rats.
    Tanaka M; Sakai A; Uchida S; Tanaka S; Nagashima M; Katayama T; Yamaguchi K; Nakamura T
    Bone; 2004 Jun; 34(6):940-8. PubMed ID: 15193540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.